Overview

An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma

Status:
Completed
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to learn about the safety and the risks of using talimogene laherparepvec in patients who already received treatment with talimogene laherparepvec in study 005/05 (NCT00769704), and to see if extended treatment with talimogene laherparepvec can destroy melanoma tumors.
Phase:
Phase 3
Details
Lead Sponsor:
BioVex Limited
Treatments:
Molgramostim
Sargramostim
Talimogene laherparepvec